Study Details
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Clinicaltrials.gov ID
Astellas Study ID
SGN22E-001
EudraCT ID
N/A
Condition
Bladder Cancer, Kidney Cancer
Phase
Phase 2
Age
18 years - N/A
Sex
Female & Male
Product
enfortumab vedotin
Type
Interventional
Trial Dates
Oct 2017 - May 2025
Masking
None (Open Label)
Enrollment number
219
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer? Contact us by filling our your information to the right and we’ll respond to you.
Locations
James Cancer Hospital / Ohio State University
Columbus, United States, 43210
Site KR82005
Daejeon, Republic of Korea
Site DE49004
Muenster, Germany
New York University (NYU) Cancer Institute
New York, United States, 10016
Site JP81011
Fukuoka, Japan
Site JP81005
Chiba, Japan
James P. Wilmot Cancer Center / University of Rochester Medical Center
Rochester, United States, 14642
Vanderbilt University Medical Center
Nashville, United States, 37204
Massachusetts General Hospital
Boston, United States, 02114
Kaiser Permanente San Leandro
San Leandro, United States, 94577
Site JP81002
Morioka, Japan
H. Lee Moffitt Cancer Center & Research Institute
Tampa, United States, 33612
Thomas Jefferson University
Philadelphia, United States, 19107
Arizona Oncology Associates, PC - HOPE
Tucson, United States, 85710
Augusta University
Augusta, United States, 30912
Site JP81010
Tokushima, Japan
Site JP81006
Shinjuku-ku, Japan
Yale Cancer Center
New Haven, United States, 06520
Arizona Oncology Associates, PC - HAL
Goodyear, United States, 85395
Site JP81007
Osaka, Japan
University of California Irvine - Newport
Orange, United States, 92868
Site NL31001
Amsterdam, Netherlands
Site DE49001
Tübingen, Germany
Kaiser Permanente Sacramento
Sacramento, United States, 95825
Site ES34004
Sevilla, Spain
Site FR33001
Villejuif-Cedex-France, France
Site ES34002
Barcelona, Spain
Keck Medical Center / Newport Beach
Newport Beach, United States, 92663
Mount Sinai Medical Center
New York, United States, 10029
Texas Oncology - Baylor Sammons Cancer Center
Dallas, United States, 75246
Kaiser Permanente Walnut Creek
Walnut Creek, United States, 94596
Site JP81009
Ube, Japan
Keck Medical Center / University of Southern California
Los Angeles, United States, 90033
Site JP81012
Fukuoka, Japan
Site JP81003
Nigata, Japan
Chao Family Comprehensive Cancer Center University of California Irvine
Orange, United States, 92868
Kaiser Permanente San Jose
San Jose, United States, 95119
Site ES34003
Santander, Spain
Alaska Urological Institute
Anchorage, United States, 99503
Kaiser Permanente Oakland
Oakland, United States, 94611
Kaiser Permanente San Francisco
San Francisco, United States, 94115
Site JP81004
Tsukuba, Japan
Texas Oncology - Austin Central
Austin, United States, 78731
Duke University Medical Center
Durham, United States, 27710
Seattle Cancer Care Alliance / University of Washington
Seattle, United States, 98109-1023
Comprehensive Cancer Centers of Nevada
Las Vegas, United States, 89169
Kaiser Permanente Roseville
Roseville, United States, 95661
Karmanos Cancer Institute / Wayne State University
Detroit, United States, 48201
Site IT39001
Milano, Italy
Site KR82001
Seoul, Republic of Korea
Kaiser Permanente Medical Center Northern California
Vallejo, United States, 94589
Site IT39003
Terni, Italy
Kaiser Permanente Santa Clara
Santa Clara, United States, 95051
Virginia Cancer Specialists, PC
Fairfax, United States, 22031
Site JP81001
Hirosaki, Japan
Houston Methodist Cancer Center
Houston, United States, 77030
Kaiser Permanente South San Francisco
South San Francisco, United States, 94080
Site KR82004
Seoul, Republic of Korea
Cleveland Clinic
Cleveland, United States, 44195
Rocky Mountain Cancer Centers - Aurora
Aurora, United States, 80012
Site KR82002
Seoul, Republic of Korea
Virginia Oncology Associates
Norfolk, United States, 23502
Dana Farber Cancer Institute
Boston, United States, 02215
Site KR82003
Seongnam-si, Republic of Korea
Site JP81008
Osakasayama, Japan
Site ES34005
Barcelona, Spain
Mayo Clinic Arizona
Phoenix, United States, 85054
University of Chicago Medical Center
Chicago, United States, 60637-1470
Johns Hopkins Medical Center
Baltimore, United States, 21231
University of Virginia
Charlottesville, United States, 22903
Washington University in St Louis
St. Louis, United States, 63110
University of California Davis
Sacramento, United States, 95817
Memorial Sloan Kettering Cancer Center
New York, United States, 10065
Maryland Oncology Hematology, P.A.
Rockville, United States, 20850
Ocala Oncology Center
Ocala, United States, 34474
Northwest Cancer Specialists, P.C.
Tigard, United States, 97223
New York Oncology Hematology, P.C.
Albany, United States, 12208
Columbia University Medical Center
New York, United States, 10032
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center
Pittsburgh, United States, 15232
Prisma Health
Greenville, United States, 29615
Norton Cancer Institute, St. Matthews Campus
Louisville, United States, 40207
The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website
© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
POWERED BY:
